Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ascendis Pharma A/S - Ordinary Share (NQ:ASND)

216.00 -2.84 (-1.30%)
Streaming Delayed Price Updated: 11:14 AM EDT, Jun 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ascendis Pharma A/S - Ordinary Share

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Recap: Ascendis Pharma Q3 Earnings ↗
 
Via Benzinga
News headline image
Preview: Ascendis Pharma's Earnings ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings for Ascendis Pharma ↗
 
Via Benzinga
News headline image
Impact on BioMarin's Sentiment: Voxzogo's Triumph Clouded by Uncertainty ↗
Raymond James initiated coverage on BioMarin Pharmaceuticals Inc (NASDAQ: BMRN) with a Market Perform rating, noting sparsity in  
Via Benzinga
News headline image
The Latest Analyst Ratings for Ascendis Pharma ↗
 
Via Benzinga
News headline image
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Earnings Preview For Ascendis Pharma ↗
 
Via Benzinga
News headline image
Analyst Expectations for Ascendis Pharma's Future ↗
 
Via Benzinga
News headline image
Where Ascendis Pharma Stands With Analysts ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings for Ascendis Pharma ↗
 
Via Benzinga
News headline image
FDA Rejects Ascendis Pharma's TransCon PTH For Hypoparathyroidism ↗
The FDA issued a complete response letter (CRL) for Ascendis Pharma A/S's 
Via Benzinga
News headline image
Earnings Scheduled For September 5, 2023 ↗
Companies Reporting Before The Bell • Procaps Gr (NASDAQ:PROC) is likely to report earnings for its second quarter. 
Via Benzinga
News headline image
Bragar Eagel & Squire, P.C. Is Investigating Ascendis, Alvotech, Shift4, and Waldencast and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Is Investigating Zai Lab, Hayward, Ascendis, and Alvotech and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Why Shares of Ascendis Pharma Are Climbing Monday ↗
A critical response letter from the FDA means hope remains for the company's hyperthyroidism therapy candidate. 
Via The Motley Fool
News headline image
Why Ascendis Pharma Stock Is Crashing This Week ↗
The FDA put a roadblock in the path to market for Ascendis' hypoparathyroidism drug. 
Via The Motley Fool
News headline image
NASDAQ: ASND Investor Alert: Investigation over Potential Wrongdoing at Ascendis Pharma A/S ↗
San Diego, CA -- (SBWIRE) -- 06/20/2023 -- Certain directors of Ascendis Pharma A/S are under investigation over potential breaches of fiduciary duties by certain directors. 
Via SBWire
News headline image
Bragar Eagel & Squire, P.C. Is Investigating C3.ai, Ascendis, Alvotech, and Shift4 and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
US Stocks Rise; Norwegian Cruise Line Posts Q1 Results ↗
U.S. stocks traded higher this morning, ahead of the Federal Reserve’s monetary policy meeting. Following the market opening Monday, the Dow traded up 0.15% to 34,147.97, while the NASDAQ inched up... 
Via Benzinga
News headline image
IVERIC bio, Ascendis Pharma And Other Big Stocks Moving Higher In Monday's Pre-Market Session ↗
U.S. stock futures traded mixed this morning. Here are some big stocks recording gains in today’s pre-market trading session. Apollomics, Inc. (NASDAQ: APLM) surged 58.4% to $7.35 in pre-market trading... 
Via Benzinga
News headline image
Bragar Eagel & Squire, P.C. Is Investigating Fox, Ascendis, and Shift4 and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Hedge Funds Fall Short: Underperforming Low-Cost S&P 500 ETF By 6% In 2023. Here's Why. ↗
So far, 2023 has not started well for the hedge fund sector, as a common SPDR S&P 500 Trust ETF (ARCA: SPY) fared much better than the Global X Guru Index ETF (ARCA: GURU), a fund that invests in the... 
Via Benzinga
News headline image
NASDAQ: ASND Shareholder Notice: Investigation over Possible Securities Laws Violations by Ascendis Pharma A/S ↗
San Diego, CA -- (SBWIRE) -- 04/17/2023 -- Ascendis Pharma A/S is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
News headline image
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Ascendis Pharma Investors to Inquire About Securities Class Action Investigation - ASND
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
ASCENDIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Ascendis Pharma A/S on Behalf of Ascendis Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 5, 2023 ↗
 
Via Benzinga
News headline image
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Ascendis Pharma A/S (ASND) Investigation
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 4, 2023 ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.